Multiple eruptive ulcers in a patient with quiescent ulcerative colitis

Angela Tewari ST6 dermatology SpR, Asif Mahmood consultant gastroenterologist, Christopher Harland consultant dermatologist
St Helier Hospital, Carshalton, UK

A 65 year old man with ulcerative colitis presented with a one week history of rapidly expanding, painful, necrotic ulcers over the lower limbs, perineum, and peristomal skin. He had no bowel symptoms. Eighteen months earlier he had undergone a subtotal colectomy and stoma formation. His ulcerative colitis was then in remission and he had been treatment free since then.

On examination he was pyrexial and drowsy with a Glasgow coma scale of 14/15. His stoma was functioning well. Multiple purple edged ulcers with central slough (fig 1) affected large areas of both legs as well as a 10×5 cm area in the right groin. There was also a peristomal ulcer surrounding the entire stoma site. Blood results are shown in table 1.

Surgical debridement was cancelled after review by a dermatologist. All wound swabs and blood cultures remained negative.

Questions

1. What is the diagnosis?
2. What is the link between this condition and inflammatory bowel disease?
3. What are the treatment options for this condition?

Answers

1.

What is the diagnosis?

Painful rapidly growing ulcers on a background of ulcerative colitis is consistent with ulcerative pyoderma gangrenosum and peristomal pyoderma gangrenosum.

Pyoderma gangrenosum typically starts as small papules and rapidly evolves. It is often misdiagnosed as infection or vasculitis. Wound cultures are often negative initially; however, after skin breakdown these wounds are subject to secondary infection.

Inflammatory markers may be raised because of underlying systemic disease. They may also be raised with the degree of inflammation associated with pyoderma gangrenosum.

Pyoderma gangrenosum is idiopathic in up to 50% of cases but can be associated with ulcerative colitis, myelodysplasia, lymphomas, arthritides, and certain drugs.1-3

Different presentations of pyoderma gangrenosum are presented in box 1.

Box 1: Types of pyoderma gangrenosum and their presentations

<table>
<thead>
<tr>
<th>Type</th>
<th>Presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ulcerative pyoderma gangrenosum</td>
<td>Rapidly evolving ulcerations with typical well defined violaceous borders. Most common and can be the most severe</td>
</tr>
<tr>
<td>Pustular pyoderma gangrenosum</td>
<td>Discrete pustules, with a surrounding erythematous halo, commonly associated with inflammatory bowel disease</td>
</tr>
<tr>
<td>Bullous pyoderma gangrenosum</td>
<td>Grouped vesicles coalescing to form large bullae. Often associated with myelodysplastic conditions</td>
</tr>
<tr>
<td>Vegetative pyoderma gangrenosum</td>
<td>Presents as erythematous ulcerated plaques without a characteristic undermined border. May develop erosions</td>
</tr>
<tr>
<td>Peristomal pyoderma gangrenosum</td>
<td>Can occur around the stoma site as a result of trauma and the pathergy response. Onset ranges from two weeks to three years after stoma formation</td>
</tr>
</tbody>
</table>

Correspondence to A Tewari angela.tewari@nhs.net
Around 2-8.5% of patients with ulcerative colitis may develop pyoderma gangrenosum. The condition occurs less commonly with Crohn’s disease.

The cytokine profile in patients with ulcerative colitis is a risk factor, regardless of bowel status, and pyoderma gangrenosum may develop after total or subtotal colectomy and in the absence of symptoms of ulcerative colitis.

Some cases of pyoderma gangrenosum improve after proctocolectomy, and therefore the pathogenesis of the condition was initially thought to relate to the activity of the bowel disease. We suspect that neutrophilic dysfunction in ulcerative colitis leads to inflammation and an influx of IL1β, TNFα, IL6, IL8, IL17, IL23, and matrix metalloproteinases, which likely play a role in the pathogenesis of pyoderma gangrenosum. These cytokines can also be found in pyoderma gangrenosum histology samples.

Genetic susceptibility to developing pyoderma gangrenosum and other extra intestinal manifestations of ulcerative colitis remains inherent despite bowel/rectal resection, even in the absence of ulcerative colitis symptoms.

What is the link between this condition and inflammatory bowel disease?

Approximately 30-60% of pyoderma gangrenosum cases are associated with ulcerative colitis.

Around 2-8.5% of patients with ulcerative colitis may develop pyoderma gangrenosum. The condition occurs less commonly with Crohn’s disease.

The cytokine profile in patients with ulcerative colitis is a risk factor, regardless of bowel status, and pyoderma gangrenosum may develop after total or subtotal colectomy and in the absence of symptoms of ulcerative colitis.

Some cases of pyoderma gangrenosum improve after proctocolectomy, and therefore the pathogenesis of the condition was initially thought to relate to the activity of the bowel disease. We suspect that neutrophilic dysfunction in ulcerative colitis leads to inflammation and an influx of IL1β, TNFα, IL6, IL8, IL17, IL23, and matrix metalloproteinases, which likely play a role in the pathogenesis of pyoderma gangrenosum. These cytokines can also be found in pyoderma gangrenosum histology samples.

Genetic susceptibility to developing pyoderma gangrenosum and other extra intestinal manifestations of ulcerative colitis remains inherent despite bowel/rectal resection, even in the absence of ulcerative colitis symptoms.

2. What is the link between this condition and inflammatory bowel disease?

Learning points

- Ulcerative pyoderma gangrenosum involves rapidly evolving ulcerations with typical well defined violaceous borders
- It is the most common form of PG and can be the most severe
- It is linked with UC in 30-60% of cases
- Onset of peristomal pyoderma gangrenosum at the stoma site can occur anywhere from two weeks to three years after stoma formation.

Patient outcome

Broad spectrum antibiotics and high dose corticosteroid therapy resulted in a substantial clinical improvement. After the addition of mycophenolate mofetil, the ulcers healed with cribriform scarring over the course of three months, and the patient will remain on mycophenolate mofetil for six months.

Patient consent obtained.

Competing interests The BMJ has judged that there are no disqualifying financial ties to commercial companies. The authors declare the following other interests: none

Further details of The BMJ policy on financial interests is here: https://www.bmj.com/about-bmj/resources-authors/forms-policies-and-checklists/declaration-competing-interests

Provenance and peer review: not commissioned; externally peer reviewed.

Study limitations

- The study was not powered to detect a difference in outcomes.
- The study was not randomized.
- The study was not blinded.

Table 1

<table>
<thead>
<tr>
<th>Test/unit</th>
<th>Result</th>
<th>Normal range</th>
</tr>
</thead>
<tbody>
<tr>
<td>C-reactive protein (mg/L)</td>
<td>200</td>
<td>&lt;4</td>
</tr>
<tr>
<td>White cell count/×10^9/L</td>
<td>15</td>
<td>4–11</td>
</tr>
<tr>
<td>Neutrophil count/×10^9/L</td>
<td>14.1</td>
<td>1.5–8</td>
</tr>
</tbody>
</table>

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions

10. Ormerod AD, Thomas KS, Craig FE, et al. UK Dermatology Clinical Trials Network STOP G. Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial. BMJ 2015;350:h2958. 10.1136/bmj.h2958. 26071094

ENDGAMES